Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

By HospiMedica International staff writers
Posted on 21 Jan 2025

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. More...

Late-stage detection often results in major surgeries, such as bladder removal and the use of an artificial bladder or urine pouch, which significantly impact the patient’s quality of life. However, current urine test kits are not very sensitive, and cystoscopy, which involves inserting a catheter into the urethra to examine the bladder, is both painful and inconvenient. This situation highlights the critical need for a simple yet reliable diagnostic method for patients. Now, a new urine-based diagnostic kit has been developed that can accurately detect bladder cancer biomarkers without the need for preprocessing the urine samples.

This innovative diagnostic tool was developed by a research team at the Korea Institute of Science and Technology (KIST, Seoul, Republic of Korea), using a method based on water and oil layering to detect biomarkers of bladder cancer. Detecting biomarkers in urine has been challenging due to their low concentration and interference from impurities like hematuria. The newly designed kit overcomes these obstacles by employing a mechanism in which a film bonded to the biomarker breaks apart, releasing a buoyant signal carrier that moves to the oil layer and emits a detectable signal. This design eliminates interference from impurities like hematuria and amplifies the signal, allowing for accurate biomarker detection. In clinical trials involving 80 patients and 25 healthy individuals, conducted with a double-blind approach, the diagnostic kit achieved a sensitivity of 88.8%, which is a substantial improvement over the mere 20% sensitivity of existing commercial tests.

Importantly, while traditional methods are almost unable to diagnose early-stage bladder cancer, the new kit is effective in identifying even early-stage cases. This diagnostic tool offers a groundbreaking approach for the early detection of bladder cancer through a simple, non-invasive urine test. It is expected to reduce the reliance on cystoscopy, improve survival rates through early detection, and enhance patients’ quality of life. Building on these promising results, the research team plans to develop products suitable for mass use in comprehensive medical centers and for easy home application.

“This study demonstrates the potential for early bladder cancer diagnosis using a simple diagnostic kit, reducing the need for unnecessary cystoscopies,” said Dr. Youngdo Jeong from KIST who led the research team.

Related Links:
KIST


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.